# A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

> **NCT01501799** · NA · COMPLETED · sponsor: **Actavis Mid-Atlantic LLC** · enrollment: 885 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** adapalene 0.1% and benzoyl peroxide 2.5% topical gel
- **DRUG:** EPIDUO
- **DRUG:** Placebo (Vehicle Gel)

## Key facts

- **NCT ID:** NCT01501799
- **Lead sponsor:** Actavis Mid-Atlantic LLC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 885 (ACTUAL)
- **Last updated:** 2011-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01501799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01501799, "A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01501799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*